FDA’s review of MDMA for PTSD highlights study bias and safety concerns ( arstechnica.com )
The comments section on this article is illuminating beyond the story itself (as is frequently the case on Ars) and worth a look....
The comments section on this article is illuminating beyond the story itself (as is frequently the case on Ars) and worth a look....